Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Payer Access Special Feature: Straining the system

Current health systems built to evaluate and pay for traditional drugs are going to struggle with gene and other unusual therapies – but manufacturers can take steps before launch to define how manufacturers assess and value these new products.

Read More »

Annual Report 2018: State of the Bio Industry

This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.

Read More »

Biomarker Development: Unlocking the Promise of Cancer Immune Therapy

Emboldened by 2017’s back-to-back FDA approvals of the first drugs that use genetically engineered patient immune cells – Kymriah (tisagenlecleucel) to treat leukemia and Yescarta (axicabtagene ciloleucel) to combat large-B-cell lymphomas – immunotherapy researchers are continuing to revolutionizing cancer treatment. But uneven patient response rates and the side effects often associated with immunotherapies are putting high priority on accurately identifying which patients would benefit most from particular treatment options.

Read More »

Consumer/Patient Experience Special Feature: Saving lives isn’t enough anymore

Pharma marketers must listen to their customers and find ways to smooth the patient journey if they are to create effective customer experiences and create loyalty beyond the first prescription.

Read More »

Consumer/Patient Experience Special Feature: Testing your CX

Want to measure your CX IQ? Answer these questions.

Read More »

Consumer/Patient Experience Special Feature: Digital therapeutics – Improving the patient experience at scale

It’s no surprise that the patient experience with the healthcare system often leads to frustration and despair. With chronic disease affecting around 50 percent of the U.S. population, it puts into perspective the sheer volume of patient experiences that are being generated each day and the magnitude of the problems that need solving. The high cost of therapies, the long wait to see a physician, the administrative burden of getting a prior authorization…the list goes on. But the day is coming, and in some cases it’s already here, where a patient could have a robust health system right in their pocket.

Read More »

Consumer/Patient Experience Special Feature: Masters Of The Pharma Universe: 4 Databases Every Digital Marketer Must Know

Nearly two-thirds of U.S. senior business decision-makers rank big data/analytics first among the technologies necessary for enhancing the customer experience. A similar number put “improving data analysis capabilities” at the top of their priorities.

Read More »

DTC Special Feature: Which color is it?

A recent study of DTC advertising appearing in the Journal of General Internal Medicine concluded that few broadcast ads are compliant with FDA’s guidelines. The reality, though, might not be so cut and dried.

Read More »

Has Trump been good for medical marketing?

While many of us from blue states and urban bubbles fret over some of the actions of President Donald Trump, it’s good to take a clear-eyed view of whether or not Trump and this administration has been good for the medical marketing industries. Moreover, it’s useful to consider how a “blue wave” in the midterm elections might change the dynamic.

Read More »

In a precision medicine environment, reducing supply chain friction factors will be key to success

It’s not hard to see how precision medicine will re-make the world of research and development and manufacturing and distribution for pharmaceutical and medical product companies. But it will make new demands on the supply chains of these organizations.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2018 Focus: Top 50 Pharma, Company of the Year and more!

Subscribe

Ad Right Bottom